c

Naia Rare Diseases Announces UK Clinical Trial Authorisation for NB 1001 for Short Bowel Syndrome – Nov 15 2017

Naia Rare Diseases today announced that it has received Clinical Trial Authorisation from the Medicine and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom to initiate a clinical trial of its long-acting GLP-1 agonist, NB 1001, in adult patients with SBS.

Read More

c

Naia Rare Diseases Secures Investment from Cedars-Sinai Health System – April 03 2017

Naia Rare Diseases today announced that Cedars-Sinai will participate in its ongoing Series B financing round.

Read More

c

Naia Rare Diseases Announces Investigational New Drug Application Submission to Initiate Clinical Trials of NB 1001 for Short Bowel Syndrome – Dec 01 2016

Naia Rare Diseases today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 1b clinical trial for its long-acting GLP-1 agonist, NB 1001, in adult patients with SBS.

Read More

c

Naia Rare Diseases Inc to Present at 28th Annual ROTH Capital Conference – Mar 11 2016

Naia Rare Diseases today announced that it will be presenting at the 28th Annual ROTH Capital Conference on Tuesday, March 15, 2016. The Conference will be held at the Ritz Carlton in Dana Point, California.

Read More

c

Naia Rare Diseases Inc appoints Professor Palle Bekker Jeppesen to its Scientific Advisory Board – Jan 18 2016

Naia Limited today announced that its subsidiary, Naia Rare Diseases, has appointed Professor Palle Bekker Jeppesen, MD, Head of Research at the Department of Gastroenterology, Rigshospitalet, Copenhagen, to its Scientific Advisory Board.

Read More

c

Naia Rare Diseases Inc Forms Scientific Advisory Board Comprised of Internationally Renowned Experts and Scientists – Jan 07 2016

Naia Limited today announced that its subsidiary, Naia Rare Diseases, has formed a Scientific Advisory Board (SAB) comprised of internationally renowned experts and scientists in gastrointestinal diseases, particularly Short Bowel Syndrome (SBS).

Read More

c

Naia Rare Diseases, has been granted orphan drug designation for NB1001 by the U.S. Food and Drug Administration (FDA) – Oct 20 2015

Naia Limited today announced that its subsidiary, Naia Rare Diseases, has been granted, by the U.S. Food and Drug Administration (FDA), orphan drug designation for NB1001, its long-acting GLP-1 receptor agonist, for the treatment of Short Bowel Syndrome (SBS).

Read More

c

Naia Limited Successfully Completes Pre-IND Meeting with US FDA for NB1001, Long-Acting GLP-1 (XTEN™-GLP-1) Receptor Agonist for Treatment of Short Bowel Syndrome – Oct 12 2015

Naia Limited, an international drug development company with an initial portfolio of innovative, clinical-stage compounds for short bowel syndrome, NASH and Type 2 diabetes, today announced that its subsidiary, Naia Rare Diseases Inc. successfully completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA).

Read More